In the series of trials with the common acronym SUPRASS, several benefits of tirzepatide in terms of metabolic control of diabetes and weight loss were demonstrated—the drug appeared to be more effective as compared to placebo, insulin degludec and glargine, and even as compared to semaglutide and dulaglutide [64,99,100,101,102,103]. Here, INS is linked to diabetes mellitus.